Str (Ectdmodule1usa1)
Chemical structure of Levetiracetam, showing a pyrrolidone ring attached to an ethyl group and a carbamoyl group at the chiral carbon.*
Levetiracetam Tablet
Product Images NDC 13668-014
17 FDA label images from Torrent Pharmaceuticals Limited · Packaging, Regulatory Labels, and Product Appearance
Product Visual Gallery
This gallery contains 17 technical images submitted to the FDA as part of the official labeling for Levetiracetam (NDC 13668-014). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.
As provided by Torrent Pharmaceuticals Limited, these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.
Product Images & Figures Index
Figure-1 (Figure 1)
A bar chart showing the percentage of patients in three groups: Placebo (N=95) with 7.4%, Levetiracetam 1,000 mg/day (N=97) with 37.1%, and Levetiracetam 3,000 mg/day (N=101) with 39.6%. The chart compares patient response rates across different dosage levels of Levetiracetam and placebo.*
Figure-2 (Figure 2)
A bar chart showing the percentage of patients across three groups: Placebo (6.3%), Levetiracetam 1,000 mg/day (20.8%), and Levetiracetam 2,000 mg/day (35.2%). The y-axis represents the percentage of patients from 0% to 45%, and the x-axis displays the treatment groups with their sample sizes (N).*
Figure-3 (Figure 3)
A bar chart comparing the percentage of patients between two groups: Placebo (N=104) and Levetiracetam 3,000 mg/day (N=180). The Placebo group shows approximately 14.4% of patients, while the Levetiracetam group shows about 39.4% of patients.*
Fig 4 (Ectdmodule1usa5)
A bar chart comparing the percentage of patients responding in two groups: Placebo (N=97) at 19.6% and Levetiracetam (N=101) at 44.6%. The vertical axis represents the percentage of patients, ranging from 0% to 45%.*
5 (Ectdmodule1usa6)
A bar graph compares the percentage of patients in two groups: Placebo with 51 participants and Levetiracetam with 58 participants. The placebo group shows approximately 19.6% of patients, while the Levetiracetam group shows about 43.1%, indicating a higher patient percentage in the Levetiracetam group.*
Fig 6 (Ectdmodule1usa7)
A bar graph comparing the percentage of patients between two groups: Placebo (N=84) with 45.2% and Levetiracetam (N=79) with 72.2%. The vertical axis is labeled '% of Patients' ranging from 0% to 100%. An asterisk is present above the Levetiracetam bar.*
Logo (Ectdmodule1usa8)
Image (Ectdmodule1usa9)
250-mg-indrad (250mg Indrad)
Levetiracetam Tablets USP 250 mg oral tablet label showing package quantity of 60 tablets. The label includes storage instructions, dispensing guidelines, manufacturer information for Torrent Pharmaceuticals Limited, and an NDC barcode. The label indicates prescription use only with a pharmacist instruction to dispense with a medication guide.*
500-mg-indrad (500mg Indrad)
Label for Levetiracetam Tablets USP, 500 mg, oral tablets by Torrent Pharmaceuticals Limited. The label indicates a package of 60 tablets with NDC 13668-015-60. Storage instructions specify keeping the product at 20° to 25°C with allowed excursions. The label includes a pharmacist note about dispensing the medication guide separately.*
750-mg-indrad (750mg Indrad)
Levetiracetam Tablets, USP 750 mg oral tablet label for a 60-tablet bottle by Torrent Pharmaceuticals Limited. The label includes storage instructions, dosage guidance, manufacturer information for Torrent Pharmaceuticals LTD and Torrent Pharma INC, a barcode, and notation that the product is prescription only.*
1000-mg-indrad (1000mg Indrad)
Levetiracetam Tablets USP 1000 mg oral tablets label for a 60 tablet package by Torrent Pharmaceuticals Limited. The label includes storage instructions, a note to dispense with medication guide, NDC 13668-017-60, and manufacturer information for Torrent Pharmaceuticals and Torrent Pharma.*
250-mg-dahej (250mg Dahej)
Levetiracetam Tablets, USP 250 mg oral tablets label for a bottle of 60 tablets. The label includes storage instructions, dispensing requirements, and a reference for dosage information. Manufactured by Torrent Pharmaceuticals Limited and labeled for Torrent Pharma Inc. The NDC code 13668-014-60 is visible along with a barcode.*
500-mg-dahej (500mg Dahej)
Label for Levetiracetam Tablets, USP 500 mg, oral tablets, containing 60 tablets per container. The label includes storage instructions, dosing notice, and pharmacist dispensing guidance. The product is manufactured by Torrent Pharmaceuticals Limited and includes the NDC 13668-015-60. The label also displays barcodes and trademark information for Torrent Pharma.*
750-mg-dahej (750mg Dahej)
Levetiracetam Tablets USP 750 mg oral tablets packaging label showing a count of 60 tablets. The label includes storage instructions, manufacturer information for Torrent Pharmaceuticals Limited, and notes dispensing with Medication Guide separately. The NDC code 13668-016-60 is displayed along with the Torrent Pharma logo.*
1000-mg-dahej (1000mg Dahej)
Levetiracetam Tablets, USP 1000 mg oral tablets packaging label for a 60-tablet bottle. Label includes storage instructions, dosage guidance, and a note for pharmacists to dispense with a medication guide. Manufactured by Torrent Pharmaceuticals Limited and labeled for prescription use only.*
* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.
